论文部分内容阅读
Aim: To investigate the regularity between the genetic, ungenetic factors of patients and the medication of FK506 in renal transplantation recipients in the first 3 month post-transplantaton, and determine the appropriate dosage of FK506 in patients with different phenotypes at different stage after transplantation.